You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

455 Results
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Mar 2021
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Soft Tissue, 
Uterine
Intent: Palliative, Adjuvant
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Nov 2024
Regimen
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB Limited Use
    denosumab (Wyost™ brand) - For the treatment of bony metastases for patients with hormone refractory prostate cancer as determined by an elevated PSA level, or evidence of progressive bony disease, despite castrate serum testosterone levels or having undergone orchidectomy, according to clinical criteria
New Drug Funding Program
    Denosumab (Biosimilar) - Hormone Refractory Prostate Cancer
Sep 2024

Pages